AKT1 and female reproductive organ cancer: These results indicate that Akt pathway and EGFR may not be completely responsible, but cooperate in the resistance of gynecological cancer cells to matuzumab and suggest a rationale for the design of clinical strategies directed to patients displaying a resistant profile to anti-EGFR therapies.